Melanoma & Skin Cancer | Specialty

FDA Grants Orphan Drug Designation to Cavrotolimod for Merkel Cell Carcinoma

March 5th 2021

The FDA has granted an orphan drug designation to cavrotolimod for the treatment of patients with Merkel cell carcinoma.

Dr. Atkins on the Efficacy of Dabrafenib/Trametinib in BRAF-Mutated Melanoma

March 1st 2021

Michael B. Atkins, MD, discusses the efficacy of dabrafenib plus trametinib in patients with BRAF-mutated melanoma.

NeoVax Demonstrates Long-Lasting Durable Responses in Melanoma

February 26th 2021

Neoantigen long peptide vaccines continued to show durable T-cell responses in patients with high-risk melanoma that persisted 4 years after initial vaccination.

Dr. Gibney on Determining Optimal Treatment Duration With Anti–PD-1 Agents in Melanoma

February 26th 2021

Geoffrey T. Gibney, MD, discusses efforts made to determine the optimal duration of treatment with anti–PD-1 agents in patients with melanoma.

Dr. Davies on the Utility of Retreatment With BRAF/MEK Inhibitors in BRAF-Mutant Melanoma

February 24th 2021

Michael A. Davies, MD, PhD, discusses the utility of retreatment with combination BRAF/MEK inhibitors in BRAF-mutant melanoma.

Combos Lead Excitement in BRAF+ Melanoma, But More Pain Points Are Ready to Be Tackled

February 18th 2021

Michael A. Davies, MD, PhD, discusses how he currently approaches treatment for patients advanced BRAF-mutant melanoma as well as exciting areas of current research to address ongoing questions in the community.

Dr. Davies on Selecting Between Combination Regimens in BRAF-Mutant Melanoma

February 17th 2021

Michael A. Davies, MD, PhD, discusses factors to consider when selecting between combination regimens in BRAF-mutant melanoma.

Neoadjuvant Tavokinogene Telseplasmid Plus Nivolumab Under Evaluation in Advanced Melanoma

February 17th 2021

The first patient with operable, locally or regionally advanced melanoma has been dosed with the intratumoral DNA plasmid-based interleukin-12 therapy tavokinogene telseplasmid in combination with nivolumab as a neoadjuvant treatment before surgery in the investigator-initiated, phase 2 OMS-104 trial.

FDA Approves Cemiplimab for Advanced Basal Cell Carcinoma

February 9th 2021

February 9, 2021 - The FDA has approved cemiplimab-rwlc as the first immunotherapy for use in patients with advanced basal cell carcinoma that has previously been treated with a hedgehog pathway inhibitor (HHI) or for whom a HHI is not appropriate.

Dr. Sullivan on Future of Triplet Therapies in Melanoma

February 9th 2021

Ryan Sullivan, MD, discusses the future of triplet therapies for patients with melanoma.